Overexpression of MTA1 promotes invasiveness and metastasis of ovarian cancer cells.
OBJECTIVE
To investigate the effect of metastasis-associated gene MTA1 on proliferation and invasion potential of ovarian cancer cell line A2780.


METHODS
The eukaryotic expressing vector pcDNA3. 1-MTA1 was introduced into A2780 cells by gene transfection in vitro. The MTA1 mRNA and protein level in cancer cells were detected by reverse transcription polymerase chain reaction (RT-PCR) and western blot, respectively. The growth activities of cancer cells were detected by trypan blue stain method. The clone formation assay in soft agar was used to observe the proliferation of cancer cells. Wound healing assay and Transwell assay were used to evaluate migration and invasion abilities of cancer cells. And the protein level of bcl-xL in ovarian cancer cells was measured by immunohistochemistry and western blot. The TUNEL assay was performed to study the apoptosis of tumor cells.


RESULTS
Seventy-two hours after transfection, the MTA1 expression increased significantly (P < 0.01). The up-regulation of MTA1 did not affect the growth activities of cancer cells (P > 0.05), but it promoted clone formation, migration and invasion abilities of cancer cells (P < 0.01). The cellular expression of bcl-xL increased 65.22 %, with a PI value of (71.64 ± 5.96) %. With the up-regulation of MTA1 and bcl-xL level, the apoptotic rate of A2780 cell was decreased.


CONCLUSIONS
MTA1 gene plays an important role in progression and metastasis of ovarian cancers, which provides an ideal strategy for gene therapy of ovarian cancers.
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang, Ave 1277#, Hubei, Wuhan, 430022, China.
X
X
He
C
C
Zhou
L
L
Zheng
Z
Z
Xiong
D017209:Apoptosis; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D018450:Disease Progression; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D009361:Neoplasm Invasiveness; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology*; D012333:RNA, Messenger / Q000378:metabolism; D012097:Repressor Proteins / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015534:Trans-Activators; D014162:Transfection; D015854:Up-Regulation; D051020:bcl-X Protein / Q000378:metabolism
C494811:BCL2L1 protein, human; C089320:MTA1 protein, human; D012333:RNA, Messenger; D012097:Repressor Proteins; D015534:Trans-Activators; D051020:bcl-X Protein; D006655:Histone Deacetylases